Evolving Global Regulatory Science Through the Voluntary Submission of Data

A 2013 Assessment

Elizabeth Gribble Walker, Martha Brumfield, Carolyn Compton, Raymond Woosley

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Regulatory science, the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated medical products, has advanced over time due to a number of factors. The FDA, the EMA, and the Pharmaceuticals and Medical Devices Agency (PMDA) have recently formalized voluntary data submission processes for the regulatory "qualification" of novel tools and methodologies for use in drug development. While recognizing that other mechanisms exist within the research community for driving scientific consensus on novel tools and methodologies, this article focuses on the formal regulatory process that addresses a tool's acceptability for incorporation by any sponsor into novel medical product development. Guidances, regulatory qualification opinions, and publications were reviewed to allow a systematic comparison of the process, content, and volume of submissions at the FDA, EMA, and PMDA. Qualification of new tools by regulatory agencies and subsequent adoption by drug developers are anticipated to speed therapeutic development for patients in need, build scientific consensus as to the usefulness and readiness of novel methodologies for understanding disease and therapeutic development, and decrease uncertainty between the regulators and sponsors regarding the appropriate application of new tools.

Original languageEnglish (US)
Pages (from-to)236-245
Number of pages10
JournalTherapeutic Innovation and Regulatory Science
Volume48
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Pharmaceutical Preparations
Equipment and Supplies
Uncertainty
Publications
Safety
Therapeutics
Research

Keywords

  • biomarker
  • critical path initiative
  • Critical Path Institute
  • drug development tool
  • European Medicines Agency
  • Food and Drug Administration
  • harmonization
  • novel methodology
  • Pharmaceuticals and Medical Devices Agency
  • qualification
  • regulatory science

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Evolving Global Regulatory Science Through the Voluntary Submission of Data : A 2013 Assessment. / Walker, Elizabeth Gribble; Brumfield, Martha; Compton, Carolyn; Woosley, Raymond.

In: Therapeutic Innovation and Regulatory Science, Vol. 48, No. 2, 2014, p. 236-245.

Research output: Contribution to journalArticle

Walker, Elizabeth Gribble ; Brumfield, Martha ; Compton, Carolyn ; Woosley, Raymond. / Evolving Global Regulatory Science Through the Voluntary Submission of Data : A 2013 Assessment. In: Therapeutic Innovation and Regulatory Science. 2014 ; Vol. 48, No. 2. pp. 236-245.
@article{47872f5e0f7c431fa160472717f95f77,
title = "Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment",
abstract = "Regulatory science, the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated medical products, has advanced over time due to a number of factors. The FDA, the EMA, and the Pharmaceuticals and Medical Devices Agency (PMDA) have recently formalized voluntary data submission processes for the regulatory {"}qualification{"} of novel tools and methodologies for use in drug development. While recognizing that other mechanisms exist within the research community for driving scientific consensus on novel tools and methodologies, this article focuses on the formal regulatory process that addresses a tool's acceptability for incorporation by any sponsor into novel medical product development. Guidances, regulatory qualification opinions, and publications were reviewed to allow a systematic comparison of the process, content, and volume of submissions at the FDA, EMA, and PMDA. Qualification of new tools by regulatory agencies and subsequent adoption by drug developers are anticipated to speed therapeutic development for patients in need, build scientific consensus as to the usefulness and readiness of novel methodologies for understanding disease and therapeutic development, and decrease uncertainty between the regulators and sponsors regarding the appropriate application of new tools.",
keywords = "biomarker, critical path initiative, Critical Path Institute, drug development tool, European Medicines Agency, Food and Drug Administration, harmonization, novel methodology, Pharmaceuticals and Medical Devices Agency, qualification, regulatory science",
author = "Walker, {Elizabeth Gribble} and Martha Brumfield and Carolyn Compton and Raymond Woosley",
year = "2014",
doi = "10.1177/2168479013508941",
language = "English (US)",
volume = "48",
pages = "236--245",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Evolving Global Regulatory Science Through the Voluntary Submission of Data

T2 - A 2013 Assessment

AU - Walker, Elizabeth Gribble

AU - Brumfield, Martha

AU - Compton, Carolyn

AU - Woosley, Raymond

PY - 2014

Y1 - 2014

N2 - Regulatory science, the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated medical products, has advanced over time due to a number of factors. The FDA, the EMA, and the Pharmaceuticals and Medical Devices Agency (PMDA) have recently formalized voluntary data submission processes for the regulatory "qualification" of novel tools and methodologies for use in drug development. While recognizing that other mechanisms exist within the research community for driving scientific consensus on novel tools and methodologies, this article focuses on the formal regulatory process that addresses a tool's acceptability for incorporation by any sponsor into novel medical product development. Guidances, regulatory qualification opinions, and publications were reviewed to allow a systematic comparison of the process, content, and volume of submissions at the FDA, EMA, and PMDA. Qualification of new tools by regulatory agencies and subsequent adoption by drug developers are anticipated to speed therapeutic development for patients in need, build scientific consensus as to the usefulness and readiness of novel methodologies for understanding disease and therapeutic development, and decrease uncertainty between the regulators and sponsors regarding the appropriate application of new tools.

AB - Regulatory science, the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of regulated medical products, has advanced over time due to a number of factors. The FDA, the EMA, and the Pharmaceuticals and Medical Devices Agency (PMDA) have recently formalized voluntary data submission processes for the regulatory "qualification" of novel tools and methodologies for use in drug development. While recognizing that other mechanisms exist within the research community for driving scientific consensus on novel tools and methodologies, this article focuses on the formal regulatory process that addresses a tool's acceptability for incorporation by any sponsor into novel medical product development. Guidances, regulatory qualification opinions, and publications were reviewed to allow a systematic comparison of the process, content, and volume of submissions at the FDA, EMA, and PMDA. Qualification of new tools by regulatory agencies and subsequent adoption by drug developers are anticipated to speed therapeutic development for patients in need, build scientific consensus as to the usefulness and readiness of novel methodologies for understanding disease and therapeutic development, and decrease uncertainty between the regulators and sponsors regarding the appropriate application of new tools.

KW - biomarker

KW - critical path initiative

KW - Critical Path Institute

KW - drug development tool

KW - European Medicines Agency

KW - Food and Drug Administration

KW - harmonization

KW - novel methodology

KW - Pharmaceuticals and Medical Devices Agency

KW - qualification

KW - regulatory science

UR - http://www.scopus.com/inward/record.url?scp=84895438216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895438216&partnerID=8YFLogxK

U2 - 10.1177/2168479013508941

DO - 10.1177/2168479013508941

M3 - Article

VL - 48

SP - 236

EP - 245

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 2

ER -